clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03018223 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | United States of America | Q30 |
P582 | end time | 2018-11-01 | |
P1050 | medical condition | leukemia | Q29496 |
lymphoma | Q208414 | ||
multiple myeloma | Q467635 | ||
chronic idiopathic myelofibrosis | Q3857106 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 34 | |
P4844 | research intervention | sirolimus | Q32089 |
fludarabine phosphate | Q185916 | ||
(RS)-cyclophosphamide | Q408524 | ||
sargramostim | Q3950557 | ||
P580 | start time | 2017-01-10 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation |